al, 1998). GDNF preferentially binds GFRα-1 (GDNF Family Receptor alpha one, also known as GDNFR-α, RETL1 and TrnR1) with high affinity before this complex can interact with RET to effect downstream signalling (Jing et al, 1996; Treanor et al, 1996; Trupp et al, 1996; Vega et al, 1996; Davies et al, 1997; Sanicola et al, 1997) . Similarly, NTN binds a membrane-bound adaptor GFRα-2 (related to GFRα-1 and also known as GDNFR-β, NTNR-α, RETL2 and TrnR2) with subsequent binding of RET (Baloh et al, 1997; Buj-Bello et al, 1997; Klein et al, 1997; Sanicola et al, 1997) . GDNF can bind GFRα-2 as well, but with lower affinity, just as NTN can also bind GFRα-1 Sanicola et al, 1997) . A third co-receptor belonging to the same family, GFRα-3, has been identified, although formal binding studies have yet to be reported Naveilhan et al, 1998; Worby et al, 1998) . Recently, a fourth co-receptor, GFRα-4, was isolated that seems to be more closely related to GFRα-1 and GFRα-2 than to GFRα-3 . Together with RET, GFRα-4 forms a functional receptor complex for persephin (Enokido et al, 1998) .
Mice lacking RET or GDNF have been shown to have defects in the enteric nervous system and components of the peripheral nervous system (Schuchardt et al, 1994; Moore et al, 1996; Pichel et al, 1996; Sanchez et al, 1996) . GDNF, like NTN, was initially isolated due to its ability to sustain the survival of embryonic dopaminergic neurons in vitro (Lin et al, 1993) . In vivo studies subsequently demonstrated that GDNF was a target-derived trophic factor for dopaminergic neurons (Stromberg et al, 1993; Hudson et al, 1995; Tomac et al, 1995) . In several animal models of Parkinson's Mutation and deletion analysis of GFRα-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours disease, a disease in which dopaminergic neurons degenerate, treatment with GDNF has a protective effect (Lindsay, 1995; Moore et al, 1996) . GDNF is, therefore, thought to play a key role in the control of vertebrate neuron survival and differentiation in both the central and peripheral nervous systems (Pichel et al, 1996) .
Taking these data together, GDNF and GFRα-1 appear to represent good targets for mutations which may play a pathogenetic role in the development of brain tumours. Additionally, the localization of GFRα-1 to 10q26 (Gorodinsky et al, 1997; Eng et al, 1998) , a region known to be somatically deleted at high frequency in malignant human brain tumours (Fults and Pedone, 1993) , further supports its candidacy as a brain tumour gene.
MATERIALS AND METHODS

Patient samples
A panel of 36 sporadic brain tumours of various histologies and WHO grades (Table 1) , from 36 unrelated German patients, was analysed. Tumour DNA was extracted from fresh frozen tissue and corresponding germline DNA from peripheral blood leucocytes, using standard protocols (Sambrook et al, 1989) .
Mutation analyses
Polymerase chain reaction (PCR) conditions and primers to amplify GDNF have been described Marsh et al, 1997) . PCR of GFRα-1 was carried out using 1 µM each of forward and reverse primer pairs (see below) in 1 × PCR buffer (Perkin-Elmer Corp.), 200 µM dNTP, 2.5 U Taq polymerase (Perkin-Elmer Corp.), TaqStart TM Antibodies (Clontech, San Francisco, CA, USA), and 100-200 ng of DNA template in a final volume of 50 µl. Reactions were subjected to 40 cycles of 94°C for 1 min, 58-62°C for 1 min and 72°C for 1 min followed by 10 min at 72°C. The PCR amplicons were then fractionated on 1% low melting point agarose (Bio-Rad Lab., Hercules, CA, USA) and visualized with UV transillumination after ethidium bromide staining. Before sequencing, these products were column purified (Wizard PCR Prep, Promega, Madison, WI, USA). Semi-automated sequencing was performed using either the forward or reverse primer and the ABI dye terminator cycle sequencing ready reaction kit as previously described .
GFRa-1 primers
Primers used to amplify GFRα-1 for sequencing are:
Deletion analysis
DNA samples derived from brain tumours which were apparently homozygous for all GFRα-1 polymorphisms underwent further analysis to determine if this represented hemizygous whole gene deletion. Corresponding germline DNA was examined for the presence of heterozygosity at the intragenic polymorphic sites that were apparently homozygous either by direct sequencing or differential restriction enzyme digestion. If the germline DNA was heterozygous for any one sequence variant, that tumour was defined as having loss of heterozygosity (LOH) of that marker, representing hemizygous gene deletion. If all intragenic polymorphisms were also homozygously present in the germline DNA, the result was not informative. In those cases, we performed a semiquantitative duplex PCR using the tumour-derived DNA and primers for exon 2 of GFRα-1 (RAF7, HRAR2) and those for the housekeeping gene beta-glucuronidase (GUSB) (Ivanchuk et al, 1997) . The relative amount of the GFRα-1 fragments versus that of GUSB were determined by visual inspection and densitometric scanning using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
RESULTS AND DISCUSSION
We analysed GDNF and GFRα-1 for DNA sequence variants in a panel of 36 mainly high-grade human brain tumours by direct sequencing. No mutations were found in the coding region of GDNF. Analysing GFRα-1, we detected six distinct single nucleotide polymorphisms ( Table 2 ) that have been previously found in the normal population (Myers et al, 1998) . Two of these were in the 5′ untranslated region 106 bp (-106G>A) and 78 bp (-78T>C) upstream of the translational start site. One silent basepair substitution at codon 179 (c.537T>C) and a non-coding sequence polymorphism within intron 5 (IVS5+21G>A) were also observed. The remaining two polymorphisms were in exon 2 and exon 7 and resulted in amino acid substitutions (Y85N, 253T>A; T361A, 1081A>G). For codon 85, both the amino acids tyrosine and asparagine are neutral and polar. However, tyrosine is an aromatic, polar residue while the polymorphic asparagine is small and non-aromatic. Similarly, the substitution of threonine (neutral and polar) with alanine (neutral and hydrophobic) at codon 361 could also change the structure of GFRα-1. In those cases harbouring rare and/or apparently homozygous polymorphisms that lead to amino acid substitutions, it is conceivable that the stearic structure, and presumably, function, of GFRα-1 could be subtly altered such that the other co-receptors of RET (e.g. GFRα-2 or GFRα-3) may bind preferentially to GDNF and RET, thus leading to altered activation and/or specificity. We, therefore, examined the frequency of each of the GFRα-1 single nucleotide polymorphisms in this series of patients with brain tumours and found them to be no different from those in normal controls or in non-cancer patients (Myers et al, 1999) . In addition to the six previously described single nucleotide polymorphisms, we also detected a homozygous non-coding sequence variant within intron 8, 28 basepairs downstream of the exon 8-intron 8 boundary (IVS8+28T>A) in the brain tumours of two unrelated patients (one glioblastoma multiforme, one anaplastic oligoastrocytoma). Interestingly, these two samples, together with 13 others, appeared to be homozygous at all six polymorphic sites. Further, the glioblastoma multiforme with the IVS8 sequence variant was apparently homozygous for the rare polymorphism at codon 361 (Table 2 ). Subsequent analyses of these 15 samples revealed somatic hemizygous deletion of GFRα-1 in 11 of these 15 tumours (73% of 15; 31% of total), including both tumours with the intronic sequence variant.
In the present study, we did not find any obvious disease-associated somatic GDNF or GFRα-1 intragenic mutations in DNA from human brain tumours from 36 individuals. We found seven single nucleotide polymorphisms within the genomic sequence of GFRα-1 in this series, six of which have been previously noted (Myers et al, 1999) . Of interest, we identified a novel intronic sequence variant in IVS8 in two patients. Our results indicate that intragenic mutations of GDNF and GFRα-1 are not common aetiologic events in brain tumorigenesis. However, we did find that 31% of the 36 brain tumours had hemizygous GFRα-1 deletion. This datum may support either of two postulates. First, it might well be possible that hemizygous deletion of GFRα-1 is aetiologic in the pathogenesis of brain tumours. Second, the deletion of GFRα-1 might be merely coincidental, an innocent bystander when large segments of chromosome 10q become deleted (Dalrymple et al, 1995; Simon et al, 1995; Albarosa et al, 1996) . Putative tumour suppressor genes like PTEN or DMBT have been mapped in this region Mollenhauer et al, 1997; Steck et al, 1997; Duerr et al, 1999) .
While it is obvious that 'high penetrance' mutations of GDNF and GFRα-1 are not associated with brain tumorigenesis, it is becoming more and more evident that development of a cancer can result from an interplay of either a few 'high penetrance' mutations in key genes or from several, or many, sequence variants of unknown significance (Storey et al, 1998) . In this respect, variant-variant interactions and/or variant-environment interactions may all be involved in predisposing to many common tumours. It is, therefore, intriguing that a few of these sequence variants in GFRα-1 involve amino acids (Y85N, T361A) that are highly conserved among species (rat, chicken and human) [Genbank accession #U90541, #U59486, #U97144]. Further informatics-based and functional studies need to be performed to investigate whether these 'polymorphic' amino acid changes and seemingly neutral sequence variants have any impact on the function of this receptor. 
